Abstract
Worldwide, cefazolin is one of the most commonly used antibiotics, as revealed in a recent article in this Journal,1 but until recently has had limited availability in the United Kingdom. We became interested in using cefazolin in the treatment of invasive Methicillin-susceptible Staphylococcus aureus (MSSA) infections, particularly bloodstream infections (BSI). Accumulating evidence suggests cefazolin is better tolerated than anti-staphylococcal penicillins (e.g. flucloxacillin, nafcillin, oxacillin),2,3 equally efficacious in the treatment of BSI due to MSSA,4,5 and may improve outcomes in MSSA BSI.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
